Genitope (GTOP - Cramer's Take - Stockpickr)
Drug: MyVax
Indication: B cell non-Hodgkin's lymphoma
Results expected: Fourth quarter 2007
MyVax is another cancer "vaccine," and like Favrille's Favid, is being developed as a treatment for non-Hodgkin's lyphoma. Genitope has already conducted several interim analyses of its phase III MyVax study with no success, meaning that the data weren't sufficient to show a clinical benefit. Final results are expected before the end of the year.
Test Time
Positive results will provide a boost
Company Drug Indication Results expected Trial Name
Accentia Biopharmaceuticals SinuNase Anti-bacterial, Mycobacterial, or Fungal Q4 2007 Phase III
Actelion Pharmaceuticals Veletri Coronary Artery Bypass Graft (CABG) 2H 2008 Study 1
Actelion Pharmaceuticals Tracleer Idiopathic Pulmonary Fibrosis (IPF) 2H 2008
Advanced Life Sciences Cethromycin Community Acquired Pneumonia (CAP) Q3 2007 CL-05
Advanced Magnetics Ferumoxytol Anemia Due to Chronic Renal Failure, Dialysis-Dependent Q3 2007 Phase III - DD-CKD
Altus Pharmaceuticals ALTU-135 Exocrine Pancreatic Insufficiency Mid-2008 DIGEST - Efficacy
Amgen AMG 531 Immune Thrombocytopenic Purpura (ITP) Q4 2007 Extension Study
Amgen Denosumab Hypercalcemia of Malignancy/Metastatic Bone Complications 2008 Phase III - Prostate cancer prevention
Amgen Denosumab Osteoporosis / Osteopenia 2H 2007 Phase III - Postmenopausal prevention (132 Study)
Arena Pharmaceuticals Lorcaserin Obesity Q4 2008-Q1 2009 BLOOM
AtheroGenics AGI-1067 Diabetes Mellitus, Type II Q4 2008 ANDES
AVAX Technologies M-Vax Melanoma 2008 Phase III
BioDelivery Sciences International BEMA Fentanyl Pain Indications 2H 2007
Biogen IDEC Rituxan Systemic Lupus Erythematosus (SLE) Mid-2008
Biogen IDEC Rituxan Multiple Sclerosis (MS) 1H 2008 OLYMPUS
Cadence Pharmaceuticals IV APAP Pain Indications 1H 2008 CPI-APA-301
Cell Genesys GVAX Prostate Cancer Vaccine Prostate Cancer Q4 2008 VITAL-1
Cell Therapeutics Pixantrone Non-Hodgkin's Lymphoma (NHL) Q3 2007 EXTEND
Cell Therapeutics Xyotax Non-Small Cell Lung Cancer (NSCLC) Mid-2008 PGT307
Cell Therapeutics Xyotax Non-Small Cell Lung Cancer (NSCLC) 2H 2008 PGT306
Cell Therapeutics Xyotax Ovarian Cancer 2H 2008 Phase III - GOG
Cypress Bioscience Milnacipran Fibromyalgia 1H 2008 Phase III - Third Trial
Dendreon Provenge Prostate Cancer 1H 2008 IMPACT (D9902B - ALL Gleason Scores)
Favrille FavId Non-Hodgkin's Lymphoma (NHL) Q4 2007 FavId-06 (Phase III)
Genentech Avastin Breast Cancer 2008 AVADO (BO17708) - 1st Line
Genentech Avastin Breast Cancer Q4 2007 ECOG 2104
Genentech Avastin Renal Cell Cancer (RCC) Q3 2007 - Q2 2008 CALGB 90206
Genentech Avastin Pancreatic Cancer 2H 2007 AVITA (BO17706) - w/Tarceva + gemcitabine
Genentech Avastin Renal Cell Cancer (RCC) 2H 2007 Phase III - AVOREN (B017705)
Genitope MyVax Non-Hodgkin's Lymphoma (NHL) Q4 2007 Phase III (2000-03)
Genmab Ofatumumab Non-Hodgkin's Lymphoma (NHL) Q4 2007-1Q 2008 Phase III
Genmab HuMax-CD4 Cutaneous T-Cell Lymphoma (CTCL) 2008 Phase III (Pivotal)
Genta Genasense Small Cell Lung Cancer (SCLC) 2H 2007
Genzyme Clolar Acute Myelogenous Leukemia (AML) Q3 2007 AML 16 - Non-intensive
Genzyme Mozobil Bone Marrow Transplant Q3 2007 Phase III - NHL
Genzyme Mozobil Bone Marrow Transplant Q3 2007 Phase III - MM
GTC Biotherapeutics ATryn Anticoagulation Mid-2008 Phase II - DIC
GTC Biotherapeutics ATryn Anticoagulation Q4 2007 Phase III
GTx Acapodene Prostate Cancer Q1 2008 Phase III - ADT
GTx Acapodene Prostatic Intraepithelial Neoplasia (PIN) Q4 2007-Q1 2008 Phase III - Monotherapy
ImClone Systems Erbitux Non-Small Cell Lung Cancer (NSCLC) 2008 SELECT (IMCL-0452)
ImClone Systems Erbitux Non-Small Cell Lung Cancer (NSCLC) 2H 2007 FLEX (EMR-046)
ImClone Systems Erbitux Non-Small Cell Lung Cancer (NSCLC) 2H 2007 BMS-099 (Taxane)
Immtech Pharmaceuticals Pafuramidine maleate Anti-parasitic or other infectious disease 2H 2007 Phase III
Indevus Pharmaceuticals PRO 2000 HIV prevention Q4 2008-2009 Phase III (Europe)
Inspire Pharmaceuticals Denufosol tetrasodium Cystic Fibrosis 2008
InterMune Pirfenidone Idiopathic Pulmonary Fibrosis (IPF) Q4 2008-2009 CAPACITY 1
InterMune Pirfenidone Idiopathic Pulmonary Fibrosis (IPF) Q4 2008-2009 CAPACITY 2
Introgen Therapeutics Advexin Head and Neck Cancer 2H 2007 Trial 302 - with 5-FU
Introgen Therapeutics Advexin Head and Neck Cancer 2H 2007 Trial 301 - vs. Methotrexate
Keryx Biopharmaceuticals Sulonex Diabetic Nephropathy Q1 2008 Phase III
Lev Pharmaceuticals C1-INH-nanofiltered Hereditary angioedema (HAE) 2H 2007 LEVP2005-1: CHANGE Trial - Parts A and B
Ligand Pharmaceuticals Oporia Osteoporosis / Osteopenia 2H 2007 PEARL
MannKind Corporation Technosphere Diabetes Mellitus, Type II 2H 2008 Phase III (Study 103)
MannKind Corporation Technosphere Diabetes Mellitus, Type II 2H 2008 Phase III (Study 102)
MannKind Corporation Technosphere Diabetes Mellitus, Type I 2H 2008 Phase III (Study 009)
Medarex (with Johnson & Johnson) CNTO 1275 Psoriasis 2H 2007 Phase III
Medarex (with Bristol-Myers Squibb) Ipilimumab Melanoma 2008 Phase III - 1st Line with DTIC (SPA)
Medarex (with Bristol-Myers Squibb) Ipilimumab Melanoma 2H 2007 Phase II - 2nd Line monotherapy (SPA)
Medarex (with Johnson & Johnson) Golimumab Rheumatoid Arthritis (RA) 2008 T05 - Methotrexate-naive
Medarex (with Johnson & Johnson) Golimumab Rheumatoid Arthritis (RA) 2008 T06 - Methotrexate Non-responders
Medarex (with Johnson & Johnson) Golimumab Ankylosing Spondylitis 2008 T09
MGI Pharma AQUAVAN Anesthesia 2H 2007 Phase III - Bronchoscopy
MGI Pharma AQUAVAN Anesthesia 2H 2007 Phase III - Safety (Minor Surgeries)
Migenix Omigard Anti-bacterial, Mycobacterial, or Fungal 2H 2008 Phase III - CLIRS
Myriad Genetics. Flurizan Alzheimer's Disease (AD) Mid-2008 Phase III - 800mg US - mild
Neurobiological Technologies Viprinex Ischemic Stroke Q1 2008 ASP-I
Neurobiological Technologies Viprinex Ischemic Stroke Q1 2008 ASP-II
Neurochem Alzhemed Alzheimer's Disease (AD) 2H 2007 CL-758007 (North American)
Novacea Asentar Prostate Cancer 2008 ASCENT-2
Novogen Phenoxodiol Ovarian Cancer 1H 2008 OVATURE - Phase IIb/III
NPS Pharmaceuticals Teduglutide Short Bowel Syndrome (SBS) 2H 2007 Phase III - Safety and Efficacy Study
Onyx Pharmaceuticals Nexavar Non-Small Cell Lung Cancer (NSCLC) 2008 Phase III - Pivotal
Onyx Pharmaceuticals Nexavar Melanoma 2008 Phase III - ECOG2603
Optimer Pharmaceuticals OPT-80 Clostridium difficile associated Diarrhea (CDAD) 2008 Second Phase III
Optimer Pharmaceuticals OPT-80 Clostridium difficile associated Diarrhea (CDAD) 2008 PAR101.C.003
Osiris Therapeutics Prochymal Graft vs. Host Disease (GVHD) mid-2008 Steroid-Refractory
Pain Therapeutics Remoxy Pain Indications 2H 2007 Phase III - SPA
Poniard Pharmaceuticals Picoplatin Small Cell Lung Cancer (SCLC) Q4 2007 - Q1 2008 SPEAR
Progenics Pharmaceuticals Methylnaltrexone IV Postoperative Ileus 2H 2007 Phase III (1)
Replidyne Orapem Anti-bacterial, Mycobacterial, or Fungal 2H 2007 Phase III - Bronchitis
Repros Therapeutics Androxal Hypogonadism 1H 2008 Phase III
Salix Pharmaceuticals Xifaxan Clostridium difficile associated Diarrhea (CDAD) 1H 2008 Phase III vs. Vancocin
Salix Pharmaceuticals Xifaxan Hepatic Encephalopathy (HE) 1H 2008
Savient Pharmaceuticals Puricase Gout Q4 2007 GOUT 2
Savient Pharmaceuticals Puricase Gout 2H 2007 Phase II - Monotherapy
SciClone Pharmaceuticals Zadaxin Hepatitis C Q4 2007 Sigma-Tau EU Trial
Somaxon Pharmaceuticals Silenor Insomnia Q3 2007
Sonus Pharmaceuticals TOCOSOL Paclitaxel Breast Cancer Q3 2007 Phase III - Monotherapy
SuperGen Dacogen Acute Myelogenous Leukemia (AML) 2H 2007 DACO-016
The Medicines Company Cleviprex Hypertension (Systemic) Q3 2007 VELOCITY - severe
Theravance Telavancin Hospital Acquired (Nosocomial) Pneumonia (HAP) Q4 2007 ATTAIN 2
Theravance Telavancin Hospital Acquired (Nosocomial) Pneumonia (HAP) Q4 2007 ATTAIN 1
Threshold Pharmaceuticals Glufosfamide Pancreatic Cancer Q3 2007 Phase I/II - w/Gemcitabine
UCB Cimzia Psoriasis Q3 2007
United Therapeutics OvaRex Ovarian Cancer 2H 2007 IMPACT II
United Therapeutics OvaRex Ovarian Cancer 2H 2007 IMPACT I
United Therapeutics UT-15C Pulmonary Arterial Hypertension (PAH) Q3 2007 - Q1 2008 FREEDOM-M
United Therapeutics UT-15C Pulmonary Arterial Hypertension (PAH) Q3 2007 - Q1 2008 FREEDOM-C
Valeant Pharmaceuticals Retigabine Seizure Disorders 2H 2007 RESTORE 1 - N. America, Argentina, Brazil
Valeant Pharmaceuticals Retigabine Seizure Disorders 2H 2007 RESTORE 2 - EU, Israel, Australia, S. Africa
Vanda Pharmaceuticals VEC-162 Insomnia mid-2008
surf's up......crikey
